Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels.

Tessa C C JaspersCharlotte E MeijerLouis Jean VlemingCasper F M FranssenJeroen DiepstratenMichael V LukensPatricia Maria Lucia Adriana van den Bemt Barbara MaatNakisa KhorsandDaniel J Touw Jeroen V Koomen

Published in: Clinical pharmacokinetics (2022)

Mainly patients receiving hemodiafiltration and those receiving hemodialysis with a high LBM can benefit from a higher nadroparin dose than currently used in clinical practice, while having anti-Xa levels < 2.0 IU/mL.

Keyphrases

clinical practice
end stage renal disease
peritoneal dialysis
chronic kidney disease
venous thromboembolism
direct oral anticoagulants